If only one time dosing would be enough, hallelujah. But I think no patient would complain about a few more shots along the recovery way if that guarantees a better outcome. Important is survival, cure, long time protection and from what we know so far HerVaxx seems to do exactly that. But neither big pharma nor the ASX think that is worth an investment. What a world are we living in?
GLTA
Ann: Appendix 4C - Quarterly and Business Update, page-15
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
3.8¢ |
Change
0.000(0.00%) |
Mkt cap ! $386.7M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 185258 | 3.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 3.5¢ | 1613 | 1 |
View Market Depth
| Last trade - 09.13am 27/11/2024 (20 minute delay) ? |
| IMU (ASX) Chart |
Day chart unavailable
